Results 51 to 60 of about 38,144 (289)

National consensus statement on opioid agonist treatment in custodial settings. [PDF]

Med J Aust
Abstract Introduction Opioid use and dependence are prevalent among incarcerated people, contributing to elevated rates of overdose and other harms in this population. Opioid agonist treatment (OAT) has been shown to be an effective intervention to mitigate these risks. However, challenges to health care implementation in the custodial sector result in
Chan J, Cook J, Curtis M, Dunlop AJ, Morrison E, Nielsen S, Winter RJ, Naren T.   +7 more
europepmc   +2 more sources

Identification and Structural Elucidation of a New Synthetic Cannabinoid, MDMB‐5′Br‐PINACA, in Seized Herbal Materials

Drug Testing and Analysis, EarlyView.
MDMB‐5Br‐PINACA, a novel synthetic cannabinoid, was identified and structurally characterized in seized herbal products using GC‐MS, LC‐HRMS, and NMR. The discovery underscores ongoing diversification of SCs and the need for vigilant surveillance.
Alexandre Barcia de Godoi, Lucas André Zeoly, Rafael Lanaro, Ingrid Simões Oliveira, Mariana Cepollaro Diana, Mauricio Yonamine, Jose Luiz Costa   +6 more
wiley   +1 more source

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system

Drugs in Context, 2023
Opioid use disorder (OUD) is a serious medical condition with vast social, health and economic impact. Individuals with OUD are prescribed opioid agonist therapies, such as methadone, levomethadone, buprenorphine or naloxone/buprenorphine, to reduce the ...
Guido Mannaioni, Fabio Lugoboni
doaj   +1 more source

Mechanisms of spinal glial activation in chemotherapy‐induced peripheral neuropathy: Focus on microglia and astrocytes

Ibrain, EarlyView.
Chemotherapy‐induced peripheral neuropathy (CIPN) remains a major clinical challenge, with central sensitization considered an important pathological mechanism in its occurrence and persistence. This review focuses on spinal astrocytes and microglia, systematically summarizing the pathological mechanisms of spinal glial cells involved in CIPN caused by
Long Gu, Song Cao, Yonghuai Feng
wiley   +1 more source

Adverse effects of opioids prescribed in opioid agonist treatment: a systematic review protocol

, 2023
Background: Opioid agonist treatment (OAT) comprises the use of opioid agonists to replace illicit street opioids and is the treatment of choice for individuals with opioid use disorder (OUD). We aim to systematically review the risk for any type of adverse effects of OAT in patients with opioid use disorder.Methods: We aim to inform evidence-based ...
Maximilian Meyer, Christian Appenzeller-Herzog, Marco Cattaneo, Lars G. Hemkens   +3 more
openaire   +1 more source

Exploring the roles and impacts of pharmacists embedded in general practice: a scoping review

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The role of the general practice pharmacist (GPP) in Australia is not yet clearly defined, and their clinical expertise remains underutilised in general practice settings. This may be attributed to a limited understanding of pharmacists' capabilities, which can hinder optimal GPP utilisation.
Christel Chandra, Brooke Bevis, Holly Foot, Nazanin Falconer   +3 more
wiley   +1 more source

Buprenorphine maintenance treatment and its outcome among opioid dependent pregnant women: A case series from India

Indian Journal of Psychiatry
Perinatal opioid use is the major public health concern worldwide due to its hazardous effect on the mother and the developing fetus. Opioid agonist maintenance treatment with buprenorphine or methadone has been the recommended treatment for opioid ...
Piyali Mandal, Rajkumar Sanahan, Yesh Chandra Singh, Atul Ambekar   +3 more
doaj   +1 more source

Opioid use disorder and treatment: challenges and opportunities

BMC Health Services Research, 2019
Background Addiction health service researchers have focused efforts on opioid use disorder (OUD) and strategies to address the emerging public health threats associated with the epidemics of opioid use and opioid overdose.
Kim A. Hoffman, Javier Ponce Terashima, Dennis McCarty   +2 more
doaj   +1 more source

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review

Frontiers in Pharmacology, 2021
Methadone, a full opioid agonist at the mu-, kappa-, and delta-receptor, and buprenorphine, a partial agonist at the mu receptor, are first-line medications in opioid maintenance treatment.
Michael Soyka
doaj   +1 more source

Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: A retrospective data linkage study [PDF]

, 2023
Samantha Colledge‐Frisby, N. R. Jones, Louisa Degenhardt, Matthew Hickman, Prianka Padmanathan, Thomas Santo, Michael Farrell, Natasa Gisev   +7 more
openalex   +1 more source